Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K-Phos Neutral is an oral phosphate supplement consisting of a combination of sodium and potassium phosphates. It is primarily used to increase urinary phosphate levels, which helps prevent the formation of calcium-based kidney stones by acidifying the urine and binding calcium. In the context of clinical research at Yale University, it is being evaluated for its impact on cardiovascular and renal function in patients with rare genetic mineral disorders, specifically X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). The supplement acts as an exogenous source of inorganic phosphate to correct hypophosphatemia and support proper bone mineralization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on K-Phos Neutral.